Adjuvants: friends in vaccine formulations against infectious diseases

References

• World Health Organization. New Global Commitment to End Tuberculosis requires research support. 2018 Sept 18. http://www.who.int/tdr/news-room/fact-sheets/detail/tuberculosis.
   Google Scholar
• Lavelle EC, McLachlan JB. Editorial overview: immunomodulation: striking the right balance: using immunomodulators to target infectious diseases, cancer, and autoimmunity. Curr Opin Pharmacol. 2018:1–3. doi:10.1016/j.coph.2018.07.013.
   Web of Science ®Google Scholar
• Mohan T, Zhu W, Wang Y, Wang BZ. Applications of chemokines as adjuvants for vaccine immunotherapy. Immunobiology 2018;223:477–85. doi:10.1016/j.imbio.2017.12.001.
   PubMed Web of Science ®Google Scholar
• Dosler S, Karaaslan E, Gerceker AA. Antibacterial and anti-biofilm activities of melittin and colistin, alone and in combination with antibiotics against Gram-negative bacteria. J Chemother. 2016;28:95–103. doi:10.1179/1973947815Y.0000000004.
   PubMed Web of Science ®Google Scholar
• Palucka K, Banchereau J, Mellman I. Designing vaccines based on biology of human dendritic cell subsets. Immunity 2010;33:464–71. doi:10.1016/j.immuni.2010.10.007.
   PubMed Web of Science ®Google Scholar
• Longet S, Lundahl MLE, Lavelle EC. Targeted strategies for mucosal vaccination. Bioconjug Chem. 2018;29:613–23. doi:10.1021/acs.bioconjchem.7b00738.
   PubMed Web of Science ®Google Scholar
• Mori A, Oleszycka E, Sharp FA, Coleman M, Osaka Y, Singh M, O’Hagan DT, Tajber I, Corngan OI, McNeela EA, et al. The vaccine adjuvant alum inhibits IL-12 by promoting PI3 kinase signaling while chitosan does not inhibit IL-12 and enhances Th1 and Th17 responses. Eur J Immunol. 2012;42:2709–19. doi:10.1002/eji.201242372.
   PubMed Web of Science ®Google Scholar
• Carroll EC, Jin L, Mori A, Muñoz-Wolf N, Oleszycka E, Moran HBT, Mansouri S, McEntee CP, Lambe E, Agger EM, et al. The vaccine adjuvant Chitosan promotes cellular immunity via DNA sensor cGAS-STING-dependent induction of type I interferons. Immunity. 2016;44:597–608. doi:10.1016/j.immuni.2016.02.004.
   PubMed Web of Science ®Google Scholar
• Lee JB, Jang JE, Song MK, Chang J. Intranasal delivery of cholera toxin induces Th17 dominated T cell-response to bystander antigens. PLoS ONE. 2009;4:1–8. doi:10.1371/journal.pone.0005190.
   Web of Science ®Google Scholar
• Pandiyan P, Lavelle EC. Immune cells in the mucosa. Ed. Frontiers Imunol. 2016;7:657–58. doi:10.3389/fimmu.2016.00657.
   PubMedGoogle Scholar
• Longhi MP, Trumpheller C, Idoyaga J, Caskey M, Matos I, Klager C, Salazar AM, Colonna M, Steinmman RM. Dendritic cells require a systemic type I interferon response to mature and induce CD4+Th1 immunity with poly IC adjuvants. JEM 2000;206:1589–602. doi:10.1084/jem.20090247.
   Google Scholar
• Sugai T, Mori M, Nakazawa M, Ichino M, Naruto T, Kobayashi N, Kobayashi Y, Minami M, Yokota S. A CpG-containing oligodeoxynucleotide as an efficient adjuvant counterbalancing the Th1/Th2 immune response in diphtheria-tetanus-pertussis vaccine. Vaccine. 2005;23:5450–56. doi:10.1016/j.vaccine.2004.09.041.
   PubMed Web of Science ®Google Scholar
• Pirahmadi S, Zakeri S, Mehriz AA, Djadid ND, Raz-AA, Sani J. Combining Monophosphoryl Lipid A (MPL), CpG Oligodeoxynucleotide (ODN), and QS-21 Adjuvants Induces Strong and Persistent Functional Antibodies and T Cell Responses against Cell-Traversal Protein for Ookinetes and Sporozoites (CelTOS) of Plasmodium falciparum in BALB/c Mice. Infect Immun. 2019;87:e00911–18.
   Google Scholar
• Favela-Hernández JM, Balderas RI, Guerrero GG. The potential of a commercial product based on Bacillus thuringiensis Cry1A-Cry2A as a immunogen and adjuvant. Madridge J Immunol. 2018;2:58–64. doi:10.18689/mjim-1000114.
   Google Scholar
• O’Hagan DT, Valiante NM. Recent advances in the discovery and delivery of vaccine adjuvants. Nat Rev Drug Discov. 2003;2:727–35. doi:10.1038/nrd1176.
   PubMed Web of Science ®Google Scholar
• de Souza AJ, Santos LVA, Coirada FC, Boscardin SB, Santoro RD. Adjuvants: classification, modus operandi, and licensing. J Immunol Res. 2016:1–16. ID. 1469394. doi:10.1155/2016/1459394.
   Web of Science ®Google Scholar
• Di Pasquale A, Preiss S, Tavares Da Silva F, Garçon N. Vaccine adjuvants: from 1920 to 2015 and beyond. Vaccines. 2015;16:320–43. doi:10.3390/vaccines3020320.
   Google Scholar
• Reed SG, Bertholet S, Coler RN, Friede M. New horizons in adjuvants for vaccine development. Trend Immunol. 2009;30:23–30. doi:10.1016/j.it.2008.09.006.
   PubMed Web of Science ®Google Scholar
• Lebre F, Bento D, Ribeiro J, Colaço M, Borchard G, Pedroso de Lima MC, Borges O. Association of Chitosan and aluminium as a new adjuvant strategy for improved vaccination. Int J Pharm. 2017;527:103–14. doi:10.1016/j.ijpharm.2017.05.028.
   PubMedGoogle Scholar
• Lebre F, Pedroso de Lima MC, Lavelle EC, Borges O. Mechanistic study of the adjuvant effect of Chitosan-aluminum nanoparticles. Int J Pharm. 2018;552:7–15. doi:10.1016/j.ijpharm.2018.09.044.
   PubMed Web of Science ®Google Scholar
• Lin Y, Wang X, Huang X, Zhang J, Xia N, Zhao Q. Calcium phosphate nanoparticles as a new generation vaccine adjuvant. Expert Rev Vaccines. 2017;16:895–906. doi:10.1080/14760584.2017.1355733.
   PubMed Web of Science ®Google Scholar
• Lacaille-Dubois MA, Wagner H. New perspectives for natural triterpene glycosides as potential adjuvants. Phytomedicine. 2017;37:49–57. doi:10.1016/j.phymed.2017.10.019.
   Web of Science ®Google Scholar
• Fernandez-Tejada A, Chea EK, George C, Pillarsetty N, Gardner JR, Livingston PO, Ragupathi G, Lewis JS, Tan DS, Glin DY. Development of a minimal saponin vaccine adjuvant base don QS-21. Nat Chem. 2014;6:635–43. doi:10.1038/nchem.1963.
   PubMed Web of Science ®Google Scholar
• Givena BE, Geary SM, Salem AK. Nanoparticle based CpG-oligonucleotides therapy for treating allergic asthma. Immunotherapy 2018;10:595–604. doi:10.2217/imt-2017-0142.
   PubMed Web of Science ®Google Scholar
• Blaise C, Bioley G. Lipid-based particles: versatile delivery systems for mucosal vaccination against infection. Front Immunol. 2018;9:431–51. doi:10.3389/fimmu.2018.00431.
   PubMed Web of Science ®Google Scholar
• Bracci L, Canini I, Puzelli S, Sestili P, Venditti M, Spleda M, Donatelli I, Belardelli F, Proietti E. Type I IFN is a powerful mucosal adjuvant for a selective intranasal vaccination against influenza virus in mice and affects antigen capture at mucosal level. Vaccine 2005;23:2994–3004. doi:10.1016/j.vaccine.2004.12.006.
   PubMed Web of Science ®Google Scholar
• Prchal M, Pilz A, Simma O, Lingnau K, von Gabain A, Strobl B, Müller M, Decker T. Type I Interferon as mediators of immune adjuvants for T and B cell dependent acquired immunity. Vaccine 2009;275:G17–G20. doi:10.1016/j.vaccine.2009.10.016.
   Google Scholar
• Tough DF. Modulation of T-cell function by type I interferón. Immunol Cell Biol. 2012;90:493–97. doi:10.1038/icb.2012.7.
   Web of Science ®Google Scholar
• Tovey MG, Lallemand CH, Thyphronitis G. Adjuvant activity of type I interferon. Biol Chem. 2008;389:541–45. doi:10.1515/bc.2008.051.
   PubMed Web of Science ®Google Scholar
• Gonzalez-Navajas JM, Lee J, David M, Raz E. Immunomodulatory functions of type I IFNs. Nat Rev Immunol. 2012;12:125–35. doi:10.1038/nri3133.
   PubMed Web of Science ®Google Scholar
• Guerrero GG, Rangel-Moreno J, Islas-Trujillo S, Rojas-Espinoza O. Successive Intramuscular Boosting with IFN-Alpha Protects Mycobacterium bovis BCG-Vaccinated Mice against M. lepraemurium Infection. BioMed Res Int. 2015;2015:1–9. ID. 414027. doi:10.1155/2015/414027.
   Web of Science ®Google Scholar
• Rivas-Santiago, Guerrero GG. IFN-α boosting of Mycobacterium bovis BCG-vaccinated mice promoted Th1 type cytokines and protect against M. tuberculosis. Biomed Res Int. 2017; ID. 8796760. doi:10.1155/2017/8796760.
   PubMed Web of Science ®Google Scholar
• Seo MD, Won HS, Kim JH, Mishig-Ochir T, Lee BJ. Antimicrobial peptides for therapeutic applications: a review. Molecules 2012;17:12276–86. doi:10.3390/molecules171012276.
   PubMed Web of Science ®Google Scholar
• Mendez-Samperio P. Recent advances in the field of antimicrobial peptides in inflammatory diseases. Adv Biomed Res. 2013;2:50–55. doi:10.4103/2277-9175.114192.
   PubMedGoogle Scholar
• Lee J, Lee DG. Antimicrobial peptides (AMPs) with dual mechanisms: membrane disruption and apoptosis. J Microbiol Biotechnol. 2015;25:759–64. doi:10.4014/jmb.1411.11058.
   PubMed Web of Science ®Google Scholar
• Ageitos JM, Sánchez-Pérez A, Calo-Mata P, Villa TG. Antimicrobial peptides (AMPs): ancient compounds that represent novel weapons in the fight against bacteria. Biochem Pharmacol. 2017;133:117–38. doi:10.1016/j.bcp.2016.09.018.
   PubMed Web of Science ®Google Scholar
• Ladram A, Nicolas P. Antimicrobial peptides from frog skin: biodiversity and therapeutic promises. Front Biosci (Landmark Ed). 2016;21:341–1371. doi:10.2741/4461.
   Web of Science ®Google Scholar
• Bechinger B, Lohner K. Detergent-like actions of linear amphipathic cationic antimicrobial peptides. Biochim Biophys Acta. 2006;1758:1529–39. doi:10.1016/j.bbamem.2006.07.001.
   PubMed Web of Science ®Google Scholar
• Sumi CD, Yang BW, Yeo IC, Young TH. Antimicrobial peptides of the Genus Bacillus: a new era for antibiotics. Can J Microbiol. 2015;61:93–103. doi:10.1139/cjm-2014-0613.
   PubMed Web of Science ®Google Scholar
• Rončević T, Puizina J, Tossi A. Antimicrobial Peptides as Anti-Infective Agents in Pre-Post-Antibiotic Era? Int J Mol Sci. 2019;14:1–22. doi:10.3390/ijms20225713.
   Google Scholar
• Patel S, Akhtar N. Antimicrobial peptides (AMPs): the quintessential ‘Offense and Defense’ molecules are more than antimicrobials. Biomed Pharmacother. 2017;95:1276–83. doi:10.1016/j.biopha.2017.09.042.
   PubMed Web of Science ®Google Scholar
• Wilmes M, Hans-Georg Sahl HG. Defensin-based anti-infective strategies. Int J Med Microbiol. 2014;304:93–99. doi:10.1016/j.ijmm.2013.08.007.
   PubMed Web of Science ®Google Scholar
• Sambhara S, McEIhaney JE. Immunosenescence and influenza vaccine efficacy. Curr Top Microbiol Immunol. 2009;333:413–29. doi:10.1007/978-3-540-92165-3_20.
   PubMedGoogle Scholar
• Luchner M, Reinke S, Milicic A. TLR agonists as vaccine adjuvants targeting cancer and infectious disease. Pharmaceutics 2021;13:142–58. doi:10.3390/pharmaceutics13020142.
   PubMed Web of Science ®Google Scholar
• Kool M, Petrilli V, De Smedf T, Rolaz A, Hammad H, van NInwegen M, Bergen IM, Castillo R, Lambrecht BN, Tschopp J. Cutting edge: alum adjuvant stimulates inflammatory dendritic cells through activation of the NALP3 inflammasome. J Immunol. 2008;181:3755–59. doi:10.4049/jimmunol.181.6.3755.
   PubMed Web of Science ®Google Scholar
• Marrack P, McKee AS, Munks MW. Towards an understating of the adjuvant action of aluminium. Nat Rev Immunol. 2009;9:287–93. doi:10.1038/nri2510.
   PubMed Web of Science ®Google Scholar
• Kool M, Soullie T, van Nimwegen M, Willart MA, Musken F, Jung S, Hoogsteden HC, Hammad H, Lambrecht BN. Alum adjuvant boosts adaptive immunity by inducing uric acid and activating inflammatory dendritic cells. J Exp Med. 2008;205:869–82. doi:10.1084/jem.20071087.
   PubMed Web of Science ®Google Scholar
• Gavin AI, Hoebe K, Duong B, Ota T, Martin C, Beutler B, Nemazee D. Adjuvant-enhanced antibody response in the absence of Toll-like receptor signaling. Science 2006;314:1936–38. doi:10.1126/science.1135299.
   PubMed Web of Science ®Google Scholar
• Fritz JH, Ferrero RL, Philpott DJ, Girardin SE. Nod-like protein in immunity, inflammation and disease. Nat Immunol. 2006;7:1250–57. doi:10.1038/ni1412.
   PubMed Web of Science ®Google Scholar
• Franchi I, Park JH, Shaw MH, Marina-Garcia N, Chen G, Kim GY, Nuñez G. Intracellular NOD-like receptors in innate immunity, infection and disease. Cell Microbio. 2008;10:1–8. doi:10.1111/j.1462-5822.2007.01059.x.
   PubMed Web of Science ®Google Scholar
• Martinon F, Tschopp J. Inflammatory caspases and inflammasomes master switches of inflammation. Cell Death Differ. 2007;14:10–22. doi:10.1038/sj.cdd.4402038.
   PubMed Web of Science ®Google Scholar
• Petrilli VC, Dostert DA, Muruve DA, Tschopp J. The inflammasome a danger sensing complex triggering innate immunity. Curr Opi Immunol. 2007;19:615–22. doi:10.1016/j.coi.2007.09.002.
   PubMed Web of Science ®Google Scholar
• Eisenbarth SC, Colegio OR, O’Connor W, Sutterwala FS, Flavell RA. Crucial role for the Nalp3 inflammasome in the immunostimulatory properties of aluminum adjuvants. Nature 2008;453:1122–26. doi:10.1038/nature06939.
   PubMed Web of Science ®Google Scholar
• Shi Y, Evans JE, Rock KI. Molecular identification of a danger signal that alerts the immune system to dying cells. Nature. 2003;452:516–21. doi:10.1038/nature01991.
   Google Scholar
• Akira S, Takeda K. Toll-like receptor signalling. Nat Rev Immunol. 2004;4:499–511. doi:10.1038/nri1391.
   PubMed Web of Science ®Google Scholar
• Daubenberger CA. TLR9 agonists as adjuvants for prophylactic and therapeutic vaccines. Curr Opin Mol Ther. 2007;9:45–52.
   PubMed Web of Science ®Google Scholar
• Wang Y-Q, Bazin-Lee H, Evams JT, Casella CR, Mitchell TC. MPL adjuvant contains competitive antagonists of human TLR4. Front Immunol. 2020;11:577823–35. doi:10.3389/fimmu.2020.577823.
   PubMed Web of Science ®Google Scholar
• Tripathi RP, Tewari N, Dwivedi N, Trwan VK. Fighting tuberculosis: an old disease with new challenges. Med Res Rev. 2005;25:93–131. doi:10.1002/med.20017.
   PubMed Web of Science ®Google Scholar
• Didierlaurent AM, Laupieze B, Di Pasquale A, Hergli N, Collignon C, Garcon N. Adjuvant system AS01: helping to overcome the challenges of modern vaccines. Expert Rev Vaccines. 2017;16:55–63. doi:10.1080/14760584.2016.1213632.
   PubMed Web of Science ®Google Scholar
• Didierlaureant AM, Collignon C, Bourguignon P, Wouters S, Fierens K, Fochesato M, Dendouga N, Langlet CH, Melissen B, Lambrecht BN, et al. Enhancement of adaptive immunity by the human vaccine adjuvant AS01 depends on activated dendritic cells. J Immunol. 2014;193:1920–30. doi:10.4049/jimmunol.1400948.
   PubMed Web of Science ®Google Scholar
• Garçon N, Van Mechelen M. Recent clinical experience with vaccines using MPL- and QS-21-containing adjuvant systems. Expert Rev Vaccines. 2011;10:471–86. doi:10.1586/erv.11.29.
   PubMed Web of Science ®Google Scholar
• Fochesato M, Dendouga N, Boxus M. Comparative preclinical evaluation of AS01 versus other adjuvant systems in a candidate herpes zoster glycoprotein E subunit vaccine. Hum Vaccin Immunother. 2016;12:2092–95. doi:10.1080/21645515.2016.1154247.
   PubMed Web of Science ®Google Scholar
• Heath MD, Mohsen MO, de Kam P-J, Carreno VTL, Hewings SJ, Kramer MF, Kunidng TM, Bachmann MF, Skinner MA. Shaping modern vaccines: adjuvant systems using microcrystalline tyrosine (MCT ®). Front Immunol. 2020;11:59491–594923. doi:10.3389/fimmu.2020.594911.
   Web of Science ®Google Scholar
• Kim WS, Zhi Y, Guo H, Byun E-B, Lim JH, Seo HS. Promotion of cellular and humoral immunity against foot-and-mouth disease virus by immunization with virus-like particles encapsulated in monophosphoryl lipid a and liposomes. Vaccines 2020;8:633.647. doi:10.3390/vaccines8040633.
   Web of Science ®Google Scholar
• De Maagd RA, Bravo A, Berry N, Crickmore N, Schnepf HE. Structure, diversity, and evolution of proteins toxins from spore-forming entomopathogenic bacteria. Annu Rev Genet. 2003;37:409–33. doi:10.1146/annurev.genet.37.110801.143042.
   PubMed Web of Science ®Google Scholar
• De Maagd RA, Bravo A, Crickmore N. How Bacillus thuringiensis has evolved specific toxins to colonize the insect world. Trends Genet. 2001;17:193–99. doi:10.1016/s0168-9525(01)02237-5.
   PubMed Web of Science ®Google Scholar
• Salkowski CA, Detore GR, Vogel SN. Lipopolysaccharide and monophosphoryl lipid A differentially regulate interleukin-12, gamma interferon, and interleukin-10 mRNA production in mRNA production in macrophages. Infect Immun. 1997;65:3239. doi:10.1128/IAI.65.8.3239-3247.1997.
   PubMed Web of Science ®Google Scholar
• Thompson BS, Chilton PM, Ward JR, Eans JT, Mitchell TC. The low-toxicity versions of LPS, MPL, adjuvant and RC529, are efficient adjuvants for CD4+ T cells. J Leukoc Biol. 2005;78:1273–80. doi:10.1189/jlb.0305172.
   PubMed Web of Science ®Google Scholar
• Jegerlehner A, Wiesel M, Dietmeier K, Zabel F, Gatto D, Saudan P, Bachmann MF. Carrier induced epitopic suppression of antibody responses induced by virus-like particles is a dynamic phenomenon caused by carrier-specific antibodies. Vaccine 2010;28:5503–12. doi:10.1016/j.vaccine.2010.02.103.
   PubMed Web of Science ®Google Scholar
• Lycke N, Lebrero-Fernández C. ADP-ribosylating enterotoxins as vaccine adjuvants. Curr Opin Pharmacol. 2018;41:42–51. doi:10.1016/j.coph.2018.03.015.
   PubMed Web of Science ®Google Scholar
• Williams NA. Immune modulation by the cholera-like enterotoxin B-subunits: from adjuvant to immunotherapeutic. Int J Med Microbiol. 2000;290:447–53. doi:10.1016/S1438-4221(00)80062-4.
   PubMed Web of Science ®Google Scholar
• Datta SK, Sabet M, Nguyen KPI, Valdez PA, Gonzalez-Navajas JM, Islam S, Mihajlov I, Fierer J, Insel PA, Webster NJ, et al. Mucosal adjuvant activity of cholera toxin requires Th17 cells and protects against inhalation anthrax. PNAs 2010;107:10638–43. doi:10.1073/pnas.1002348107.
   PubMed Web of Science ®Google Scholar
• Cai CY, Kurita-Ochiai T, Kobayashi R, Hashizume T, Yamamoto M. Nasal immunization with the 40 KDa outer membrane protein of Porphyromonas gingivalis plus cholera toxin induces protective immunity in aged mice. J Oral Sci. 2013;55:107–14. doi:10.2334/josnusd.55.107.
   PubMed Web of Science ®Google Scholar
• Da Hora VP, Conceicao FR, Dellagostin OA, Doolan DL. Non-toxic derivatives of LT as potent adjuvants. Vaccine 2011;29:1538–44. doi:10.1016/j.vaccine.2010.11.091.
   PubMed Web of Science ®Google Scholar
• Thiam F, Chernilienne A, Poncet D, Kohh E, Basset C. B subunits of cholera toxin and thermolabile enterotoxin of Escherichia coli have similar adjuvant effect as whole molecules on rotavirus 2/6-VLP specific antibody responses and induce a Th17-like response after intrarectal immunization. Microb Pathog. 2015;89:27–34. doi:10.1016/j.micpath.2015.08.013.
   PubMed Web of Science ®Google Scholar
• Yongping M. Recent advances in nontoxic Escherichia coli heat-labile toxin and its derivative adjuvants. Expert Rev Vaccines. 2016;15:1361–71. doi:10.1080/14760584.2016.1182868.
   PubMed Web of Science ®Google Scholar
• Millar DG, Hirst TR, Snider DP. Escherichia coli heat-labile enterotoxin B subunit is a more potent mucosal adjuvant than its closely related homologue, the B subunit of cholera toxin. Infect Immun. 2001;69:3476–82. doi:10.1128/IAI.69.5.3476-3482.2001.
   PubMed Web of Science ®Google Scholar
• Rojas-Hernández S, Rodriguez-Monroy MA, López-Revilla R, Reséndiz-Albor AA, Moreno-Fierros L. Intranasal coadministration of the Cry1Ac protoxin with amoebal lysates increases protection against Naegleria fowleri meningoencephalitis. Infect Immun. 2004;72:4368–75. doi:10.1128/IAI.72.8.4368-4375.2004.
   PubMed Web of Science ®Google Scholar
• Ibarra-Moreno S, García-Hernández AL, Moreno-Fierros L. Coadministration of protoxin Cry1Ac from Bacillus thuringiensis with metacestode extract confers protective immunity to murine cysticercosis. Parasite Immunol. 2014;36:266–70. doi:10.1111/pim.12103.
   PubMed Web of Science ®Google Scholar
• González-González E, García-Hernández AL, Flores-Mejía R, López-Santiago R, Moreno-Fierros L. The protoxin Cry1Ac of Bacillus thuringiensis improves the protection conferred by intranasal immunization with Brucella abortus RB51 in a mouse model. Vet Microbiol. 2016;175:382–88. doi:10.1016/j.vetmic.2014.11.021.
   Web of Science ®Google Scholar
• Legorreta-Herrera M, Oviedo MR, Moreno-Fierros L. Pretreatment with Cry1Ac protoxin modulates the immune response,and increases the survival of Plasmodium-infected CBA/Ca mice. J Biomed Biotech. 2010;2010:1–11. ID 198921. doi:10.1155/2010/198921.
   Google Scholar
• Tundup S, Srivastava I, Harn D Jr. Polarization of the host immune responses by helminth-expressed glycans. Ann NY Acad Sci. 2012;1253:EI–EI3. doi:10.1111/j.1749-6632.2012.06618.x.
   Web of Science ®Google Scholar
• Demet CJ, Ishii KJ. Nucleic acid sensing at the interface between innate and adaptive immunity in vaccination. Nat Rev Immunol. 2012;12:479–91. doi:10.1038/nri3247.
   PubMed Web of Science ®Google Scholar
• Kubelkova K, Macela A. Innate immune recognition: an issue more complex than expected. Front Cell Infect Microbiol. 2019;9:1–19. doi:10.3389/fcimb.2019.00241.
   PubMed Web of Science ®Google Scholar
• Kumar S, Ingle H, Prasad DVR, Kumar H. Recognition of bacterial infection by innate immune sensors. Crit Rev Microbiol. 2013;39:229–46. doi:10.3109/1040841X.2012.706249.
   PubMed Web of Science ®Google Scholar
• Pulendra B, Ahmed R. Immunological mechanism of vaccination. Nat Immunol. 2011;12:509–17. doi:10.1038/ni.2039.
   PubMed Web of Science ®Google Scholar
• Fujkuyama Y, Tokuhara D, Kataoka K, Gilbert RS, McGhee JR, Yuki Y, Kiyono H. Fujihashi K novel vaccine development strategies for inducing mucosal immunity. Expert Rev Vaccines. 2012;11:367–79. doi:10.1586/erv.11.196.
   PubMed Web of Science ®Google Scholar
• Walker LS, Sansom DM. The emerging role of CTLA4 as a cell-extrinsic regulator of T cell responses. Nat Rev Immunology. 2011;11:852–63. doi:10.1038/nri3108.
   PubMed Web of Science ®Google Scholar
• Walker LSK, Lecture EFIS. Understanding the CTLA-4 checkpoint in the maintenance of immune homeostasis. Immunol Letter. 2017;184:43–50. doi:10.1016/j.imlet.2017.02.007.
   PubMed Web of Science ®Google Scholar
• Schijns VE. Immunological concepts of vaccine adjuvant activity. Curr Opin Immunol. 2000;12:456–63. doi:10.1016/s0952-7915(00)00120-5.
   PubMed Web of Science ®Google Scholar
• Yoshino S, Sasatomi E, Ohsawa M. Bacterial lipopolysaccharide acts as adjuvant to induce autoimmune arthritis in mice. Immunology 2000;4:607–14. doi:10.1046/j.1365-2567.2000.00015.x.
   Google Scholar
• van Dissel JT, Arend SM, Prims C, Bang P, Tugkov PN, Lingnau K, Nouta J, Klein MR, Rocenkrands I, Ottenhoff THM. Ag85B-ESAT-6 adjuvanted with K31 promotes strong and long-lived Mycobacterium tuberculosis specific T cell responses in naive human volunteers. Vaccine 2010;28:3571–81. doi:10.1016/j.vaccine.2010.02.094.
   PubMed Web of Science ®Google Scholar
• Fraser CK, Diener KR, Brown MP, Huyball JD. Improving vaccine by incorporating immunological adjuvants. Expert Rev Vaccines. 2007;6:559–78. doi:10.1586/14760584.6.4.559.
   PubMed Web of Science ®Google Scholar
• Locht C, Houghardy JM, Rouanet C, Place S, Mascart F. Heparin-binding haemagglutinin, from an extrapulmonary dissemination factor to a powerful diagnostic and protective antigen against tuberculosis. Tuberculosis 2006;86:303–09. doi:10.1016/j.tube.2006.01.016.
   PubMed Web of Science ®Google Scholar
• Guerrero GG, Debrie AS, Locht C. Boosting with mycobacterial heparin-binding haemagglutinin enhanced protection of Mycobacterium bovis BCG vaccinated newborns mice against M. tuberculosis. Vaccine 2010;28:4340–47. doi:10.1016/j.vaccine.2010.04.062.
   PubMed Web of Science ®Google Scholar
• Guerrero GG, Locht C. Recombinant HBHA boosting effect on BCG-induced immunity against Mycobacterium tuberculosis infection. Clin Dev Immunol. 2011;2011:730702. doi:10.1155/2011/730702.
   PubMedGoogle Scholar
• Xia S, Duan K, Zhang Y, Zhao D, Zhang H, Xie Z, Li X, Peng C, Zhang Y, Zhang W, et al. Effect of an inactivated vaccine against SARS-CoV-2 on safety and immunogenicity outcomes: interim analysis of 2 randomized clinical trials. JAMA 2020;324:951–60. doi:10.1001/jama.2020.15543.
   PubMed Web of Science ®Google Scholar
• Xia S, Zhang Y, Wang Y, Wang H, Yang Y, Gao FG, Tan W, Wu G, Xu M, Lou Z, et al. Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBIBP-CorV: a randomised, double-blind, placebo-controlled, phase 1/2 trial. Lancet Infect Dis. 2021;21:39–51. doi:10.1016/S1473-3099(20)30831-8.
   PubMed Web of Science ®Google Scholar
• Zhang Y, Zeng G, Pan H, Li C, Hu Y, Chu K, Han W, Chen Z, Tang R, Yin W, et al. Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18-59 years: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial. Lancet Infect Dis. 2021;21:181–92. doi:10.1016/S1473-3099(20)30843-4.
   PubMed Web of Science ®Google Scholar
• Keech C, Albert G, Cho I, Robertson A, Reed P, Neal S, Plested JS, Zhu M, Cloney-Clark S, Zhou H, et al. Phase 1–2 trial of a SARS-CoV-2 recombinant spike protein nanoparticle vaccine. N Engl J Med. 2020;383:2320–32. doi:10.1056/NEJMoa2026920.
   PubMed Web of Science ®Google Scholar
• Topol EJ. Messenger RNA vaccines against SARS-CoV2. Cell 2021;184:1401–02. doi:10.1016/j.cell.2020.12.039ç.
   PubMed Web of Science ®Google Scholar
• Polack FP, Thomas SJ, Kitchin N, Absalon J, Gurtman A, Lockhart S, John L, Perez GM, Moreira ED, Zerbini C, et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. Clinical Trial N Engl J Med. 2020;383:2603–15. doi:10.1056/NEJMoa2034577.
   PubMed Web of Science ®Google Scholar
• Pulendran B, Arunachalam PS, O’Hagan DT. Emerging concepts in the science of vaccine adjuvants. Nat Rev Drug Discov. 2021;6:1–22. doi:10.1038/s41573-021-00163-y.
   Google Scholar